CIK 0001714899 · Large accelerated filer
Denali Therapeutics Inc.
Sign in to watch- Ticker
- DNLI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 463872213
- Phone
- (650) 866-8547
- Business address
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- 4 Planned sale Director sold 1,666 shares at $18.42 ($30,688)
- 144 Insider Sale of Securities
- 4 Planned sale Chief Medical Officer sold 4,668 shares at $19.02 ($88,785)
- 4 Open-market sale President and CEO sold 7,818 shares at $19.78 ($154,640)
- 144 Insider Sale of Securities
- 4 Open-market sale Chief Medical Officer sold 9,972 shares at $19.43 ($193,756)
- 4 Open-market sale Director sold 3,208 shares at $19.43 ($62,331)
- 4 Open-market sale COFO and Secretary sold 9,972 shares at $19.43 ($193,756)
- 4 Open-market sale President and CEO sold 17,483 shares at $19.43 ($339,695)
- 144 Insider Sale of Securities
- 8-K Event Regulation FD disclosure
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Grant or award COFO and Secretary acquired 53,720 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 53,720 shares (grant or award)
Page 12 of 40 · 789 filings